Research Article
American Journal of BioMedicine
Volume 11, Issue 4, 2023, Pages 158-164 
10.18081/2333-5106/2023.11/158
Tetiana Prystupa 1, N. P. Obukhova *
Received 12 May 2023; revised 30 July 2023; accepted 30 August 2023; published 12 October 2023
Abstract
Red cell distribution width (RDW) measures red cells’ size variability. Metastatic ovarian cancer displays poor chemotherapy response without an effective prognostic predictor address. we investigated whether RDW correlates independently with survival outcomes in metastatic ovarian cancer treated by chemotherapy. Subsequently, it has been specified that RDW can be likewise utilized as a prognostic marker of metastatic ovarian cancer patients. Venous blood was collected from each patient in the morning. RDW was obtained directly by the hematology analyzer from 55 patients with metastatic ovarian cancer and were retrospectively analyzed between 2018 and 2022. Survival time was calculated from the date of chemotherapy initiation until the date of death.
Keywords: Red cell distribution width (RDW); Metastatic ovarian cancer; Chemotherapy
Copyright © 2023 Obukhova NP, et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cited by CrossRef (0)
Cited by Scopus ()
| 1. National Cancer Institute (2022, Oct. 14). Cancer Staging. https://www.cancer.gov/about-cancer/diagnosis-staging/staging | ||||
| 2. American Cancer Society (2018, April 11). Ovarian Cancer Stages. https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/staging.html | ||||
| 3. City of Hope (2022, July 20). Ovarian cancer stages. https://www.cancercenter.com/cancer-types/ovarian-cancer/stages | ||||
| 4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30. https://doi.org/10.3322/caac.21166 |
||||
| 5. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386(9990):249-57. https://doi.org/10.1016/S0140-6736(14)62223-6 |
||||
| 6. Xu Z, Mohile SG, Tejani MA, Becerra AZ, Probst CP, Aquina CT, et al. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal cancer: An NCDB analysis. Cancer. 2017;123(1):52-61. https://doi.org/10.1002/cncr.30261 |
||||
| 7. Torre LA, Bray F, Siegel RL, et al. Global cancer statisitics, 2012. CA Cancer J Clin 2015; 65:87-108. https://doi.org/10.3322/caac.21262 |
||||
| 8. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. European organization for research and treatment of cancer-gynaecological cancer group; NCIC clinical trials group. neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943-53. https://doi.org/10.1056/NEJMoa0908806 |
||||
| 9. Qin Y, Wang P, Huang Z, Huang G, Tang J, Guo Y, et al. The value of red cell distribution width in patients with ovarian cancer. Medicine (Baltimore). 2017;96(17): e6752. https://doi.org/10.1097/MD.0000000000006752 |
||||
| 10. Baicus C, Caraiola S, Rimbas M, Patrascu R, Baicus A. Utility of routine hematological and inflammation parameters for the diagnosis of cancer in involuntary weight loss. J Investig Med. 2021; 59:951-955. https://doi.org/10.2310/JIM.0b013e31822467a3 |
||||
| 11. Cheung M, Pei J, Pei Y, Jhanwar SC, Pass HI, Testa JR. The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene. 2010; 29:1633-40. https://doi.org/10.1038/onc.2009.455 |
||||
| 12. Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr., Skubitz AP, et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004; 93:170-81. https://doi.org/10.1016/j.ygyno.2003.12.034 |
||||
| 13. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, et al.. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014; 20:1288-97. https://doi.org/10.1158/1078-0432.CCR-13-2611 |
||||
| 14. Wirth F, Lubosch A, Hamelmann S, Nakchbandi IA. Fibronectin and its receptors in hematopoiesis. Cells. 2020; 9:2717. https://doi.org/10.3390/cells9122717 |
||||
| 15. Hu, L. et al. Prognostic value of RDW in cancers: a systematic review and meta-analysis. Oncotarget. 2017; 8:16027-16035. https://doi.org/10.18632/oncotarget.13784 |
||||
| 16. Yazici, P. et al. The role of red cell distribution width in the prognosis of patients with gastric cancer. Cancer Biomark Sect. Dis. Markers. 2017; 18:19-25. https://doi.org/10.3233/CBM-160668 |
||||
| 17. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK-PI 3 K/A kt pathway. Cell biology international. 2014; 38(1):85-91. https://doi.org/10.1002/cbin.10184 |
||||
| 18. Daly MB, Pilarski R, Yurgelun MB, et al. NCCN guidelines insights: genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020, Journal of the National Comprehensive Cancer Network. 2020; 18(4):380-391. https://doi.org/10.6004/jnccn.2020.0017 |
||||
| 19. akitas MA, Tosteson TD, Li Z, et al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol. 2015; 33(13):1438-45. https://doi.org/10.1200/JCO.2014.58.6362 |
||||
| 20. White KM, Seale H, Harrison R. Enhancing ovarian cancer care: a systematic review of guideline adherence and clinical variation. BMC Public Health. 2019; 19(1):296. https://doi.org/10.1186/s12889-019-6633-4 |
||||
| 21. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014; 384(9951):1376-88. https://doi.org/10.1016/S0140-6736(13)62146-7 |
||||
| 22. Fields EC, McGuire WP, Lin L, Temkin SM. Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future. Front Oncol. 2017; 7:177. https://doi.org/10.3389/fonc.2017.00177 |
||||
File and statistics
Permissions
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in American Journal of BioMedicine are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.